Redmile Group LLC cut its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,025,770 shares of the biopharmaceutical company’s stock after selling 986,791 shares during the quarter. Amicus Therapeutics comprises about 6.3% of Redmile Group LLC’s portfolio, making the stock its 2nd biggest holding. Redmile Group LLC owned approximately 6.03% of Amicus Therapeutics worth $144,271,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Parametric Portfolio Associates LLC acquired a new position in Amicus Therapeutics in the 2nd quarter valued at $282,000. Nationwide Fund Advisors raised its holdings in Amicus Therapeutics by 5.6% in the 3rd quarter. Nationwide Fund Advisors now owns 178,212 shares of the biopharmaceutical company’s stock valued at $2,687,000 after acquiring an additional 9,503 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in Amicus Therapeutics by 31.9% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 78,421 shares of the biopharmaceutical company’s stock valued at $1,183,000 after acquiring an additional 18,970 shares in the last quarter. Chicago Equity Partners LLC acquired a new position in Amicus Therapeutics in the 3rd quarter valued at $481,000. Finally, American Century Companies Inc. acquired a new position in Amicus Therapeutics in the 3rd quarter valued at $1,302,000.
FOLD has been the subject of several analyst reports. BidaskClub cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Zacks Investment Research cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 19th. Cowen reissued a “buy” rating and set a $22.00 price target on shares of Amicus Therapeutics in a report on Wednesday, January 10th. ValuEngine raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Robert W. Baird set a $20.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. Amicus Therapeutics has a consensus rating of “Buy” and a consensus price target of $19.06.
In related news, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.71, for a total transaction of $73,550.00. Following the sale, the insider now owns 69,184 shares in the company, valued at approximately $1,017,696.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Daphne Quimi sold 8,000 shares of the business’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total value of $117,760.00. Following the sale, the senior vice president now owns 62,676 shares in the company, valued at approximately $922,590.72. The disclosure for this sale can be found here. Insiders have sold a total of 207,870 shares of company stock worth $3,066,112 in the last 90 days. 3.40% of the stock is currently owned by corporate insiders.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $14.66 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 5.53 and a current ratio of 5.60. Amicus Therapeutics, Inc. has a fifty-two week low of $6.41 and a fifty-two week high of $17.40.
Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.11). Amicus Therapeutics had a negative return on equity of 71.06% and a negative net margin of 769.03%. The business had revenue of $14.73 million for the quarter, compared to analyst estimates of $14.50 million. sell-side analysts predict that Amicus Therapeutics, Inc. will post -1.26 earnings per share for the current fiscal year.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.